Heart disease is the leading cause of death for women in United States, killing 299,578 women in 2017—or about 1 in every 5 female deaths.1
Going beyond standard lipid panels to assess lipoprotein, apolipoprotein, inflammatory, metabolic, and genetic risk factors may provide deeper insights into the residual risk of your patients.
Our cardiovascular tests provide a more in-depth look at genetic risk factors and lifestyle factors, like smoking, diet, and stress to help you and your patients understand their cardiovascular health.
Going beyond standard lipid panels to assess lipoprotein and apolipoprotein risk factors may provide deeper insights into the residual risk of your patients. Patients who may benefit from advanced testing include those with:
Routine lipid screening plays an important role in cardiovascular risk assessment, but it may not adequately identify risk of adverse events. In fact, nearly 50% of all heart attacks and strokes occur in patients who had “normal” cholesterol levels.3 Evidence suggests that inflammation within the artery wall is a key contributor to residual risk for heart attack and stroke, contributing to both vulnerable plaque formation and to plaque rupture.
Inflammation can be easily measured with advanced testing to more fully assess cardiovascular risk. Monitoring a patient’s inflammatory status may help you to uncover hidden risk from early to advanced stages of cardiovascular disease. With deeper insights, you can take further action to help reduce your patient's cardiovascular risk.
In many patients,the risk of CVD may be attributed to genetic polymorphisms and mutations. Quest Diagnostics offers cardiogenetic testing to aid in early diagnosis and earlier treatment for affected patients, as well as family members.
Familial hypercholesterolemia (FH) refers to a group of genetic defects resulting in severe elevations of blood cholesterol levels and increased risk of premature coronary heart disease (CHD). Cardio IQ® genetic testing for FH from Quest can help you make an early, specific diagnosis of FH so you can help your patients understand their risk.
Patients who have metabolic syndrome are at higher risk of multiple chronic conditions, including diabetes, coronary heart disease, and cancer, as well as stroke. Metabolic syndrome has become increasingly common: its prevalence has risen in every sociodemographic group, and today it is estimated that more than a third of adults in the United States have metabolic risk.4 Some factors contributing to metabolic syndrome are genetic, while others can be modified with lifestyle changes.
With the US population aging, prevalence of heart failure (HF) is projected to grow by 25% and associated direct costs by 215% by 2030.5
Patients who may be at risk for developing heart failure include those with:
In addition, risk identification may serve as a wake-up call for patients of concern, eg, those not adhering to medications or otherwise not following their treatment plan.
The 4myheart® program is a personalized care platform, designed to help your patients improve and maintain heart health. The program is individualized and based on findings from each patient’s Cardio IQ® Test. The service provides access to clinical educators who work with the doctor to create a risk-reduction plan that may help patients improve their heart health. Moreover, the website is redesigned to make it patient-friendly, intuitive, and easy to navigate. Learn more
| Test name | Test Code |
Advanced Lipid Panel with Inflammation, Cardio IQ® Includes: Cardio IQ® Lipid Panel with Reflex to Direct LDL, Cardio IQ® Lipoprotein Fractionation, Ion Mobility, Cardio IQ® Apolipoprotein B, Cardio IQ® Lipoprotein (a), Cardio IQ® hs-CRP, Cardio IQ Lp-PLA2, Cardio IQ® MPO, Cardio IQ® ADMA/SDMA, Cardio IQ® OxLDL, Cardio IQ® F2-Isoprostane/Creatinine |
94220 |
Lipid Panel/ASCVD (Atherosclerotic Cardiovascular Disease) Risk Panel |
|
Lipid Panel with Reflex to Direct LDL, Cardio IQ® Includes: Cardio IQ® Cholesterol, Total Cardio IQ® HDL Cholesterol Cardio IQ® Triglycerides Cardio IQ® Non-HDL and Calculated Components If Triglyceride is >400 mg/dL, then Cardio IQ® Direct LDL will be performed at an additional charge (CPT code(s): 83721). |
92061 |
|
Includes: Cardio IQ® Cholesterol, Total Cardio IQ® HDL Cholesterol Cardio IQ® Triglycerides Cardio IQ® Non-HDL and Calculated Components |
91716 |
| Cardio IQ® ASCVD Risk Panel with Score Includes: Cardio IQ® Cholesterol, Total Cardio IQ® HDL Cholesterol Cardio IQ® Triglycerides Cardio IQ® Non-HDL and Calculated Components Cardio IQ® Direct LDL Cardio IQ® ASCVD Risk Scores If Triglyceride is >400 mg/dL, then Direct LDL will be performed at an additional charge (CPT code(s): 83721). |
92052 |
| Lipoprotein Subfractionation | |
| Cardio IQ® Lipoprotein Fractionation, Ion Mobility | 91604 |
| sdLDL | 36406 |
| Apolipoproteins | |
| Cardio IQ® Apolipoprotein B | 91726 |
| Cardio IQ® Lipoprotein (a) | 91729 |
| Inflammation | |
| F2-Isoprostane/Creatinine Ratio | 92771 |
| OxLDL | 92769 |
| ADMA/SDMA | 94153 |
| Cardio IQ® Fibrinogen Antigen, Nephelometry | 91743 |
| Cardio IQ® hs-CRP | 91737 |
| Cardio IQ® Lp-PLA2 Activity | 94218 |
| Cardio IQ® Myeloperoxidase (MPO) | 92814 |
| Metabolic markers | |
| Cardio IQ® Diabetes Risk Panel with Score | 92026 |
| Cardio IQ® Glucose | 91947 |
| Cardio IQ® Hemoglobin A1c | 91732 |
| Cardio IQ® Insulin | 91731 |
| Cardio IQ® Homocysteine | 91733 |
| OmegaCheck® | 92701 |
| TMAO (Trimethylamine N-Oxide) | 94154 |
| Cardio IQ® Vitamin D, 25-Hydroxy | 91735 |
| Heart failure | |
| Cardio IQ® NT ProBNP | 91739 |
| Cardio IQ® ST2, Soluble | 91823 |
| Galectin-3 | 92768 |
| Genetic cardiovascular markers | |
| Cardio IQ® 4q25-AF Risk Genotype | 90948 |
| Cardio IQ® APOE Genotype | 90649 |
| Cardio IQ® 9p21 Genotype | 90648 |
| Cardio IQ® CYP2C19 Genotype | 90668 |
| Cardio IQ® KIF6 Genotype | 90645 |
| Cardio IQ® LPA Aspirin Genotype | 90553 |
| Cardio IQ® LPA Intron-25 Genotype | 90655 |
Advanced cardiovascular testing provides actionable information to individualize treatment options:
Visit the resource center for additional information on Cardio IQ advanced tests
Watch Dr. Felice Gersh, Medical Director at Integrative Medical Group, and Dr. Wohlgemuth, Quest’s Chief Medical Officer, explore the prevalence of heart disease in women and the role of OB/GYNs and lab testing in identifying risk.
Test codes may vary by location. Please contact your local laboratory for more information.
References:
Image content features models and is intended for illustrative purposes only.
Review the latest data from our new 2020 Health Trends™ study.
Colorectal cancer that is caught in the early stages has a 5-year survival rate of over 90%. InSure® ONE™ makes it easy with at-home testing.
With rates of sexually transmitted infections (STIs) on the rise, assessing women who may be high-risk is more important than ever.
Contact us to receive additional information on our lab tests, services, and coverage
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.
